Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2018-08-16 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
独立董事关于公司第六届董事会第十二次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is an independent director's pre-approval opinion regarding matters to be discussed at the company's 6th Board of Directors 12th meeting. It discusses the adjustment of a 2018 non-public stock issuance plan, employee stock ownership plans, and related party transactions. The document is a formal opinion letter from independent directors, not a full report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a regulatory filing or announcement of a report publication. It relates to board-level decisions and approvals, specifically concerning board meeting agenda items and related opinions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2018-08-16 Chinese
2018年非公开发行股票预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled '非公开发行股票预案（修订稿）' which translates to 'Non-public Issuance of Shares Proposal (Revised Draft)'. It details a plan for a non-public issuance of shares by 安徽安科生物工程（集团）股份有限公司, including background, purpose, issuance objects, pricing, and use of proceeds. It references approvals by the board and shareholders, regulatory compliance with the China Securities Regulatory Commission (CSRC), and specifics about the issuance structure and restrictions. The document is comprehensive and lengthy (15,000 characters), containing detailed financial and strategic information about the capital raising. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report, nor a full annual or interim report, nor a proxy or voting document. Therefore, the correct classification is CAP.
2018-08-16 Chinese
关于公司创业板非公开发行股票申请文件反馈意见之回复报告
Capital/Financing Update Classification · 95% confidence The document is a detailed response report to feedback from the China Securities Regulatory Commission (CSRC) regarding a non-public stock issuance application by Anhui Anke Biotechnology (Group) Co., Ltd. It includes extensive information about the employee stock ownership plan subscription, subscription amounts, and compliance with regulatory requirements. The document is related to a non-public offering of shares, which is a capital raising activity. It is not an annual report, earnings release, or management discussion, but rather a regulatory filing related to capital issuance. Given the detailed nature of the response to regulatory feedback on a stock issuance application, the document fits best under Capital/Financing Update (CAP).
2018-08-16 Chinese
安徽天禾律师事务所关于公司实施第二期员工持股计划之补充法律意见书
Capital/Financing Update Classification · 95% confidence The document is a supplementary legal opinion letter issued by a law firm regarding the implementation and revision of an employee stock ownership plan (ESOP) by Anhui Anke Bioengineering (Group) Co., Ltd. It details legal compliance, procedural steps, and disclosures related to the ESOP, including references to relevant laws and regulatory approvals needed. The document is a legal opinion and not a financial report, earnings release, or regulatory filing per se. It does not contain financial statements or earnings data, nor is it a notice of voting results or management changes. It is a specialized legal opinion related to capital/financing activities (employee stock ownership plan implementation and non-public stock issuance). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6771 characters) and content confirm it is a substantive legal opinion rather than a brief announcement or certification, so it is not RNS or RPA.
2018-08-16 Chinese
关于与安徽安科生物工程（集团）股份有限公司-第2期员工持股计划签署附条件生效的非公开发行股份认购协议之补充协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a supplemental agreement to a conditional private placement subscription agreement related to an employee stock ownership plan. It details modifications to the terms of the stock subscription agreement, including pricing and subscription amounts. The document is relatively short (2210 characters) and focuses on the announcement of a financing transaction rather than providing comprehensive financial data or results. It does not contain financial statements or detailed financial analysis but rather updates on a capital raising activity through a non-public issuance of shares. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2018-08-16 Chinese
关于非公开发行股票预案（修订稿）披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (509 characters) regarding a non-public stock issuance plan (非公开发行股票预案) by 安徽安科生物工程（集团）股份有限公司. It references the disclosure of the revised plan and employee stock ownership plan drafts on a regulatory website, indicating it is an update or notice rather than the full detailed plan itself. The text explicitly states it is a "提示性公告" (prompting or indicative announcement) about the disclosure of the plan, not the plan document itself. The document length is short and it serves as a notification to investors to review the detailed documents elsewhere. According to the "MENU VS MEAL" rule, this is an announcement about a report, not the report itself. Therefore, the appropriate classification is Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes.
2018-08-16 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.